ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements
Ajanta Pharma posted robust revenue and PAT growth, primarily driven by a temporary US market upside. Management remains cautious as competition intensifies.
Ajanta Pharma Ltd reported revenue from operations of ₹1,794 Cr (+32.5% YoY) and net profit of ₹388.1 Cr (+49.2% YoY) for Q2 FY27.
Ajanta Pharma promoter Aayush Agrawal (trustee) created a pledge on 30,000 equity shares. The pledge was made as a top-up call due to share price reduction.
Ajanta Pharma has scheduled a Board meeting for 30 October 2026 to consider Q2/H1 2026 unaudited financial results. No material decision has been taken yet.
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Promoter Aayush Agrawal Trust created pledge on 4,60,000 Ajanta Pharma shares. The pledge secures an NCD issue in favor of CTL Trusteeship Ltd.
CTL Trusteeship Limited reported a pledge creation on 26,21,067 shares (2.10%) of Ajanta Pharma Limited to secure debentures worth Rs. 3,873 Crore. The shares act as collateral for NCDs issued by Lenexis Foodworks and Inspira Realty.
Ajanta Pharma promoter Aayush Agrawal Trust released a pledge on 98,185 equity shares. The release followed loan repayment to Aditya Birla Capital Ltd.
Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.
Promoter Aayush Agrawal Trust released pledge on 9.76 lakh shares and created a new pledge on 9.20 lakh shares of Ajanta Pharma Limited.
Promoter Ravi Agrawal, as trustee of Ravi Agrawal Trust, released a pledge on 54,796 equity shares of Ajanta Pharma Limited due to excess pledge.
Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.
Ajanta Pharma Limited has allotted 23,400 equity shares following the exercise of employee stock options. Consequently, the company's paid-up share capital increased to Rs. 24.99 Crore.
Ajanta Pharma Limited has fixed August 5, 2026, as the record date. This date determines shareholder eligibility for the payment of the first interim dividend.
Ajanta Pharma Ltd reported revenue from operations of ₹1,626 Cr (+24.8% YoY) and net profit of ₹334.2 Cr (+30.9% YoY) for Q1 FY27.
Ajanta Pharma promoter Aayush Agrawal released a pledge of 21,61,067 shares and simultaneously created a new pledge for the same number of shares.
Ajanta Pharma has scheduled a board meeting for July 30, 2026. The board will consider and approve the Q1 financial results.
Ajanta Pharma concluded its 47th AGM on July 16, 2026. Key resolutions included adopting FY2025-26 financial statements and confirming the interim dividend as final.
Ajanta Pharma revised its SAST filing, indicating pledged promoter shares as security for non‑convertible debentures. No monetary value of the pledge is disclosed.
Ajanta Pharma pledged shares as security for debentures totaling ₹3,873 crore. The pledge benefits CTL Trusteeship Ltd as common security trustee.
Ajanta Pharma disclosed that the US FDA inspection of its Paithan facility resulted in a Voluntary Action Indicated classification. The filing is for regulatory update only.
Promoter Ravi Agrawal Trust released pledges on 17,32,792 equity shares of Ajanta Pharma. The release was executed on June 25, 2026.
Promoter Aayush Agrawal created a pledge over 1,111,111 Ajanta Pharma shares for a new loan. The pledge increases promoter leverage and warrants monitoring.
Ajanta Pharma's 47th AGM will be held on 16 July 2026 via VC/OAVM. The notice and annual report will be dispatched to members.
Ravi Agrawal Trust, a promoter of Ajanta Pharma, sold 34,50,000 shares (2.76%) via the open market. This transaction reduces the promoter trust's stake to 10.24%.
Ajanta Pharma promoter Ravi Agrawal created a pledge on 2,20,000 shares and released 2,60,000 shares. The creation was driven by business re-financing requirements.
Ajanta Pharma promoter Aayush Agrawal released a pledge on 1,92,500 shares following loan repayment. This reduction in encumbered shares improves the promoter's skin-in-the-game.
Promoter Aayush Agrawal pledged and released 2,86,213 shares of Ajanta Pharma Limited. The transactions relate to new loan creation and existing loan repayment.
Ajanta Pharma submitted its Annual Secretarial Compliance Report for the year ended March 2026. This routine regulatory filing confirms adherence to SEBI listing obligations and disclosure requirements.
Ajanta Pharma achieved record FY26 revenue >₹5,000cr and PAT >₹1,000cr, driven by strong US and Africa performance despite Asia supply chain headwinds.